Characteristics of 10-year survivors of high-grade serous ovarian carcinoma

被引:79
|
作者
Dao, Fanny [1 ]
Schlappe, Brooke A. [1 ]
Tseng, Jill [1 ]
Lester, Jenny [2 ]
Nick, Alpa M. [3 ]
Lutgendorf, Susan K. [4 ,5 ]
McMeekin, Scott [6 ]
Coleman, Robert L. [3 ]
Moore, Kathleen N. [6 ]
Karlan, Beth Y. [2 ]
Sood, Anil K. [3 ]
Levine, Douglas A. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, Gynecol Serv, 1275 York Ave, New York, NY 10065 USA
[2] Cedars Sinai Med Ctr, Dept Obstet & Gynecol, Samuel Oschin Comprehens Canc Inst, Womens Canc Program, Los Angeles, CA 90048 USA
[3] Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNA, Dept Gynecol Oncol, Dept Canc Biol, Dallas, TX USA
[4] Univ Iowa, Holden Comprehens Canc Ctr, Dept Psychol & Brain Sci, Dept Obstet & Gynecol, Iowa City, IA 52242 USA
[5] Univ Iowa, Holden Comprehens Canc Ctr, Dept Urol, Iowa City, IA 52242 USA
[6] Univ Oklahoma, Dept Obstet & Gynecol, Stephenson Oklahoma Canc Ctr, Div Gynecol Oncol, Oklahoma City, OK USA
关键词
Ovarian cancer; Long-term survival; Neoadjuvant chemotherapy; Surgical cytoreduction; Outcome; Survival; PROGNOSTIC-FACTORS; CANCER; MORTALITY; SURGERY; DISEASE;
D O I
10.1016/j.ygyno.2016.03.010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. High-grade serous carcinoma (HGSC) generally presents at an advanced stage with poor long-term (LT) survival. Here we describe clinical features found in women surviving HGSC for ten or more years. Methods. A multi-center research consortium was established between five participating academic centers. Patient selection criteria included high-grade serous ovarian, fallopian tube, or peritoneal carcinoma with at least ten years of follow up. Non-serous, borderline tumors and low-grade serous subtypes were excluded. Results. The 203 identified LT ten-year survivors with HGSC were diagnosed at a median age of 57 years (range 37-84 years). The majority of patients had stage IIIC (72.4%) disease at presentation. Of those who underwent primary cytoreductive surgery, optimal cytoreduction was achieved in 143 (85.6%) patients. After a median follow up of 144 months, 88 (46.8%) patients did not develop recurrent disease after initial treatment. Unexpected findings from this survey of LT survivors includes 14% of patients having had suboptimal cytoreduction, 11% of patients having an initial platinum free interval of <12 months, and nearly 53% of patients having recurrent disease, yet still surviving more than ten years after diagnosis. Conclusions. LT survivors of HGSC of the ovary generally have favorable clinical features including optimal surgical cytoreduction and primary platinum sensitive disease. The majority of patients will develop recurrent disease, however many remained disease free for more than 10 years. Future work will compare the clinical features of this unusual cohort of LT survivors with the characteristics of HGSC patients having less favorable outcomes. (C) 2016 The Authors. Published by Elsevier Inc.
引用
收藏
页码:260 / 263
页数:4
相关论文
共 50 条
  • [1] Personalising Treatment for High-Grade Serous Ovarian Carcinoma
    Cojocaru, E.
    Parkinson, C. A.
    Brenton, J. D.
    CLINICAL ONCOLOGY, 2018, 30 (08) : 515 - 524
  • [2] Molecular Management of High-Grade Serous Ovarian Carcinoma
    Punzon-Jimenez, Paula
    Lago, Victor
    Domingo, Santiago
    Simon, Carlos
    Mas, Aymara
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (22)
  • [3] Precursor Lesions of High-Grade Serous Ovarian Carcinoma: Morphological and Molecular Characteristics
    Gross, Amy L.
    Kurman, Robert J.
    Vang, Russell
    Shih, Ie-Ming
    Visvanathan, Kala
    JOURNAL OF ONCOLOGY, 2010, 2010
  • [4] Clinical Outcomes of Patients with High-Grade Ovarian Carcinoma Arising in Endometriosis Compared to Ovarian High-Grade Serous Carcinoma
    Ibrahim Yalcin
    Hanifi Sahin
    Mustafa Erkan Sari
    Asuman Nihan Haberal
    Eda Adeviye Sahin
    Husnu Celik
    Mehmet Mutlu Meydanli
    Ali Ayhan
    Indian Journal of Gynecologic Oncology, 2021, 19
  • [5] Clinical Outcomes of Patients with High-Grade Ovarian Carcinoma Arising in Endometriosis Compared to Ovarian High-Grade Serous Carcinoma
    Yalcin, Ibrahim
    Sahin, Hanifi
    Sari, Mustafa Erkan
    Haberal, Asuman Nihan
    Sahin, Eda Adeviye
    Celik, Husnu
    Meydanli, Mehmet Mutlu
    Ayhan, Ali
    INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY, 2021, 19 (04)
  • [6] Serous Endometrial Intraepithelial Carcinoma with High-Grade Serous Ovarian Carcinoma: A Synchronous Presentation
    Ramya Yethadka
    Ranjitha Vodigenahalli Nagaraj
    Indian Journal of Gynecologic Oncology, 2024, 22
  • [7] Serous Endometrial Intraepithelial Carcinoma with High-Grade Serous Ovarian Carcinoma: A Synchronous Presentation
    Yethadka, Ramya
    Nagaraj, Ranjitha Vodigenahalli
    INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY, 2024, 22 (01)
  • [8] Clinicopathologic, Immunohistochemical, and Molecular Characteristics of Ovarian Serous Carcinoma With Mixed Morphologic Features of High-grade and Low-grade Serous Carcinoma
    Zarei, Shabnam
    Wang, Yan
    Jenkins, Sarah M.
    Voss, Jesse S.
    Kerr, Sarah E.
    Bell, Debra A.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2020, 44 (03) : 316 - 328
  • [9] THE ORIGIN AND CLINICAL CHARACTERISTICS OF HIGH-GRADE SEROUS CARCINOMA
    Dalaty, Mariam
    Nicodin, Ovidiu
    Popescu, Anca
    Nicodin, Mihnea Andrei
    Niculescu, Nicolae
    Criste, Simona
    Badiu, Diana
    Ghita, Constantin
    Niculescu, Costin
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 : A289 - A289
  • [10] HMGA2 and high-grade serous ovarian carcinoma
    Jingjing Wu
    Jian-Jun Wei
    Journal of Molecular Medicine, 2013, 91 : 1155 - 1165